Tag: Checkpoint Inhibitor for MCC

Home / Checkpoint Inhibitor for MCC

Categories

Retifanlimab-dlwr is approved by FDA for metastatic or recurrent locally advanced Merkel cell carcinoma

April 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cel...
checkpoint-inhibitor-for-mcc

Scan the code